[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY31128A1 - Formulacion de nevirapina de liberacion prolongada - Google Patents

Formulacion de nevirapina de liberacion prolongada

Info

Publication number
UY31128A1
UY31128A1 UY31128A UY31128A UY31128A1 UY 31128 A1 UY31128 A1 UY 31128A1 UY 31128 A UY31128 A UY 31128A UY 31128 A UY31128 A UY 31128A UY 31128 A1 UY31128 A1 UY 31128A1
Authority
UY
Uruguay
Prior art keywords
nevirapine
formulation
prolonged release
prolonged
release
Prior art date
Application number
UY31128A
Other languages
English (en)
Inventor
Feng-Jing Chen
Glen Charles Snow
Svetlana Sienkiewicz
Michael Cappola
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31128(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY31128A1 publication Critical patent/UY31128A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica de liberación prolongada que comprende nevirapina .
UY31128A 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada UY31128A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
UY31128A1 true UY31128A1 (es) 2009-01-30

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31128A UY31128A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada

Country Status (29)

Country Link
US (1) US8460704B2 (es)
EP (1) EP2155169B1 (es)
JP (1) JP5417662B2 (es)
KR (1) KR101017862B1 (es)
CN (1) CN101784263B (es)
AR (1) AR066924A1 (es)
AU (1) AU2008262031B2 (es)
BR (1) BRPI0811732A2 (es)
CA (1) CA2687491C (es)
CL (1) CL2008001678A1 (es)
CO (1) CO6150128A2 (es)
DK (1) DK2155169T3 (es)
EA (1) EA018377B1 (es)
EC (1) ECSP099561A (es)
ES (1) ES2574836T3 (es)
HK (1) HK1145806A1 (es)
HU (1) HUE028598T2 (es)
IL (1) IL199924A0 (es)
MA (1) MA31430B1 (es)
MX (1) MX2009007764A (es)
NZ (1) NZ578664A (es)
PE (2) PE20090371A1 (es)
PL (1) PL2155169T3 (es)
TN (1) TN2009000510A1 (es)
TW (1) TWI419716B (es)
UA (1) UA97971C2 (es)
UY (1) UY31128A1 (es)
WO (1) WO2008154234A2 (es)
ZA (1) ZA200904939B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2155169B1 (en) 2007-06-08 2016-03-23 Boehringer Ingelheim International GmbH Extended release formulation of nevirapine
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
AU2012264475A1 (en) 2011-05-30 2013-10-31 Cipla Limited Pharmaceutical antiretroviral composition
JP6169079B2 (ja) * 2011-08-24 2017-07-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 徐放のための活性剤の製剤
RU2014140177A (ru) * 2012-03-05 2016-04-27 Сипла Лимитед Фармацевтические антиретровирусные композиции
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
WO1999029297A1 (en) 1997-12-05 1999-06-17 Alza Corporation Osmotic dosage form comprising first and second coats
DK1140012T3 (da) 1998-12-17 2004-07-12 Alza Corp Omdannelse af væskefyldte gelatinekapsler til systemer til kontrolleret frigivelsessystemer ved flere coatinger
MX339071B (es) * 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
BRPI0014271B1 (pt) * 1999-09-24 2021-06-22 Janssen Pharmaceutica N.V. Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem
JP2003516345A (ja) 1999-12-09 2003-05-13 アルザ・コーポレーション 抗ウイルス剤
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
EP1643946A2 (en) 2003-06-20 2006-04-12 Viral Genomix, Inc. Compositions for and methods for treating hiv
CN1863512A (zh) 2003-10-01 2006-11-15 鲁宾有限公司 控释药物组合物及其制备方法
CA2545650C (en) 2003-11-13 2015-08-18 Control Delivery Systems, Inc. Injectable sustained release delivery devices
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
CN101212957A (zh) 2005-06-29 2008-07-02 万能药生物有限公司 药物缓释组合物及其制备方法
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
JP2009511191A (ja) * 2005-10-14 2009-03-19 マイクロドース・テクノロジーズ・インコーポレーテッド 経口投与剤組合せ型医薬パッケージ法
EP2155169B1 (en) 2007-06-08 2016-03-23 Boehringer Ingelheim International GmbH Extended release formulation of nevirapine

Also Published As

Publication number Publication date
EA018377B1 (ru) 2013-07-30
TW200916127A (en) 2009-04-16
JP5417662B2 (ja) 2014-02-19
CA2687491A1 (en) 2008-12-18
BRPI0811732A2 (pt) 2014-11-18
CL2008001678A1 (es) 2009-09-11
EP2155169A2 (en) 2010-02-24
PL2155169T3 (pl) 2016-09-30
PE20131035A1 (es) 2013-10-01
KR20100020447A (ko) 2010-02-22
JP2010520891A (ja) 2010-06-17
NZ578664A (en) 2011-11-25
WO2008154234A9 (en) 2009-11-26
CN101784263A (zh) 2010-07-21
MA31430B1 (fr) 2010-06-01
WO2008154234A2 (en) 2008-12-18
KR101017862B1 (ko) 2011-03-04
EA200900958A1 (ru) 2010-04-30
ECSP099561A (es) 2009-09-29
TWI419716B (zh) 2013-12-21
CN101784263B (zh) 2012-11-07
DK2155169T3 (en) 2016-06-13
UA97971C2 (ru) 2012-04-10
CA2687491C (en) 2011-09-20
IL199924A0 (en) 2010-04-15
WO2008154234A3 (en) 2010-01-21
US8460704B2 (en) 2013-06-11
TN2009000510A1 (en) 2011-03-31
AU2008262031B2 (en) 2011-08-25
MX2009007764A (es) 2009-09-10
EP2155169B1 (en) 2016-03-23
US20100278918A1 (en) 2010-11-04
CO6150128A2 (es) 2010-04-20
HUE028598T2 (en) 2016-12-28
HK1145806A1 (en) 2011-05-06
PE20090371A1 (es) 2009-04-24
ZA200904939B (en) 2010-04-28
AR066924A1 (es) 2009-09-23
ES2574836T3 (es) 2016-06-22
AU2008262031A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
HN2008001191A (es) Compuestos de biciclolactama sustituida
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
HN2011003195A (es) Modulares de gpr 119
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
HN2008001103A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BRPI0918360A2 (pt) composto, composição farmacêutica e usos de um composto
ECSP10010295A (es) Formulacion de anticuerpo
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
HN2012000437A (es) Nuevos agentes anticancer y la preparacion de dichos agentes
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
ES2465478T8 (es) Composiciones farmacéuticas que comprenden brivaracetam
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
HN2008001521A (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171006